Randomized phase II trial of the cyclin-dependent kinase inhibitor Dinaciclib (MK-7965) versus capecitabine in patients with advanced breast cancer

Clinical Breast Cancer

Volumn 14, Issue 3, 2014, Pages 169-176

  Mita, Monica M ^a   Joy, Anil A ^b   Mita, Alain ^a   Sankhala, Kamalesh ^a   Jou, Ying Ming ^c   Zhang, Da ^c   Statkevich, Paul ^c   Zhu, Yali ^c   Yao, Siu Long ^c   Small, Karen ^c   Bannerji, Rajat ^c   Shapiro, Charles L ^d  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF ALBERTA   (Canada)

^c MERCK RESEARCH LABORATORIES   (United States)

^d THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

Efficacy; Monotherapy; Safety; Small molecule inhibitor; Solid tumors

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CAPECITABINE; DINACICLIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; FLUOROURACIL; FUSED HETEROCYCLIC RINGS; PYRIDINIUM DERIVATIVE;

ABDOMINAL PAIN; ADULT; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER FATIGUE; CANCER GRADING; CANCER PATIENT; CANCER PROGNOSIS; CANCER THERAPY; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL ARTICLE; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DIARRHEA; DISEASE COURSE; DIZZINESS; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXPOSURE; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LEUKOPENIA; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MULTIPLE DRUG DOSE; PAROXYSMAL DYSPNEA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL; POSITIONAL DIZZINESS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN FISSURE; STOMATITIS; AGED; ANALOGS AND DERIVATIVES; BREAST NEOPLASMS; CLINICAL TRIAL; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PROPORTIONAL HAZARDS MODEL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BICYCLO COMPOUNDS, HETEROCYCLIC; BREAST NEOPLASMS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PYRIDINIUM COMPOUNDS;

EID: 84899988247     PISSN: 15268209     EISSN: 19380666     Source Type: Journal    
DOI: 10.1016/j.clbc.2013.10.016     Document Type: Article

References (30)

1. ® (capecitabine) [prescribing information]: South San Francisco, CA: Genentech USA Inc; 2011. Available at: http://www.gene.com/ download/pdf/xeloda-prescribing.pdf.
2. ® (ixabepilone) [prescribing information]: Princeton, NJ: Bristol-Myers Squibb; 2011. Available at: http://packageinserts. bms.com/pi/pi-ixempra.pdf.
3. ® (eribulin mesylate) [prescribing information]: Woodcliff Lake, NJ: Eisai, Inc; 2012. Available at: http://halaven.com/sites/ default/files/HALAVEN-full-Prescribing-Information.pdf.
4. G.I. Shapiro Cyclin-dependent kinase pathways as targets for cancer treatment J Clin Oncol 24 2006 1770 1783
5. C. Abdullah, X. Wang, and D. Becker Expression analysis and molecular targeting of cyclin-dependent kinases in advanced melanoma Cell Cycle 10 2011 977 988
6. J.L. Dean, A.K. McClendon, and T.E. Hickey et al. Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors Cell Cycle 11 2012 2756 2761
7. I.N. Hahntow, F. Schneller, and M. Oelsner et al. Cyclin-dependent kinase inhibitor Roscovitine induces apoptosis in chronic lymphocytic leukemia cells Leukemia 18 2004 747 755
8. N. Johnson, and G.I. Shapiro Cyclin-dependent kinases (CDKs) and the DNA damage response: rationale for CDK inhibitor-chemotherapy combinations as an anticancer strategy for solid tumors Expert Opin Ther Targets 14 2010 1199 1212
9. D.W. McMillin, J. Delmore, and J. Negri et al. Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implications Br J Haematol 152 2011 420 432
10. V. Quereda, and M. Malumbres Cell cycle control of pituitary development and disease J Mol Endocrinol 42 2009 75 86
11. + disease Breast Cancer Res 11 2009 112
12. D. Parry, T. Guzi, and F. Shanahan et al. Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor Mol Cancer Ther 9 2010 2344 2353
13. G. Feldmann, A. Mishra, and S. Bisht et al. Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models Cancer Biol Ther 12 2011 598 609
14. W. Fu, L. Ma, and B. Chu et al. The cyclin-dependent kinase inhibitor SCH 727965 (dinaciclib) induces the apoptosis of osteosarcoma cells Mol Cancer Ther 10 2011 1018 1027
15. D. Horiuchi, L. Kusdra, and N.E. Huskey et al. MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition J Exp Med 209 2012 679 696
16. B.C. Nair, S. Vallabhaneni, R.R. Tekmal, and R.K. Vadlamudi Roscovitine confers tumor suppressive effect on therapy-resistant breast tumor cells Breast Cancer Res 13 2011 R80
17. K.T. Flaherty, P.M. Lorusso, and A. Demichele et al. Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer Clin Cancer Res 18 2012 568 576
18. M.M. Mita, A.C. Mita, and J. Moseley et al. A phase I study of the CDK inhibitor Dinaciclib (SCH727965) administered every 3 weeks in patients (pts) with advanced malignancies: Final results J Clin Oncol 29 2011 Abstract 3080
19. J. Nemunaitis, M. Saltzman, and M.A. Rosenberg et al. A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of SCH 727965, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies J Clin Oncol 27 2009 (abstract 3535)
20. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
21. O. Miettinen, and M. Nurminen Comparative analysis of two rates Stat Med 4 1985 213 226
22. D. Zhang, M. Mita, and G.I. Shapiro et al. Effect of aprepitant on the pharmacokinetics of the cyclin-dependent kinase inhibitor dinaciclib in patients with advanced malignancies Cancer Chemother Pharmacol 70 2012 891 898
23. NONMEM. Version V Level 1.1 2004 ICON Development Solutions Ellicott City, Maryland
24. P.F. Thall, L.H. Wooten, and N.M. Tannir Monitoring event times in early phase clinical trials: some practical issues Clin Trials 2 2005 467 478
25. A. Nanos-Webb, N.A. Jabbour, and A.S. Multani et al. Targeting low molecular weight cyclin E (LMW-E) in breast cancer Breast Cancer Res Treat 132 2012 575 588
26. C. Mitchell, A. Yacoub, and H. Hossein et al. Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo Cancer Biol Ther 10 2010 903 917
27. M.N. Fornier, D. Rathkopf, and M. Shah et al. Phase I dose-finding study of weekly docetaxel followed by flavopiridol for patients with advanced solid tumors Clin Cancer Res 13 2007 5841 5846
28. D.J. Slamon, S.A. Hurvitz, and S. Applebaum et al. Phase I study of PD 0332991, cyclin-D kinase (CDK) 4/6 inhibitor in combination with letrozole for first-line treatment of patients with ER positive, HER2-negative breast cancer J Clin Oncol 28 2010 (abstract 3060)
29. R.S. Finn, J.P. Crown, and I. Lang et al. Results of a randomized phase 2 study of PD 0332991, a cyclin dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (BC) Cancer Res 72 2012 (abstract S1-6)
30. R. Booher, H. Hirsch, P. Strack, L. Zawel, and S. Fawell Mcl-1 dependency is a predictive biomarker for apoptotic induction by short-term dinaciclib (SCH 727965) treatment Cancer Res 72 2012 (abstract 3063)